Protocol: V114-002-008, "A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of a Pneumococcal Conjugate Vaccine (V114) Compared to Pneumococcal Polysaccharide Vaccine (PNEUMOVAX 23) and Prevnar 13 (Pneumococcal 13-Valent

Project: Other project

StatusFinished
Effective start/end date3/1/126/14/19

Funding

  • Merck Sharp & Dohme Corporation: $31,413.33